Table 1.

Characteristics of included studies

Study	Country	Study interval	Study design	LOEa	Treatment regimen	Number of patients, conbercept/ranibizumab
Cai and Peng,17 2016	People’s Republic of China	2013–2015	Retrospective	2b	Monthly	30/30
Cui et al,18 2018	People’s Republic of China	2014–2015	Retrospective	2b	As-needed	83/85
Huang et al,19 2018	People’s Republic of China	2013–2016	Retrospective	2b	Monthly for 3 months then as-needed	35/44
Li et al,20 2018	People’s Republic of China	2016–2017	RCT	2b	Monthly for 3 months then as-needed	20/20
Lv et al,21 2016	People’s Republic of China	2013–2015	RCT	2b	Monthly for 3 months then as-needed	42/42
Niu et al,22 2016	People’s Republic of China	2014–2015	RCT	2b	Monthly	20/20
Yang,23 2018	People’s Republic of China	2014–2016	RCT	2b	As-needed	24/24
Zhang and Zhao,24 2016	People’s Republic of China	2014–2016	RCT	3b	Monthly	25/25
Zhang,25 2017	People’s Republic of China	2015–2016	RCT	2b	Monthly	20/20
Zhang and Bai,26 2017	People’s Republic of China	2014–2016	RCT	3b	Monthly	49/49
Zhao and Bai,27 2015	People’s Republic of China	2013–2014	Retrospective	2b	Monthly for 3 months then as-needed	30/31
Zheng,28 2017	People’s Republic of China	2013–2014	RCT	2b	Monthly for 3 months then as-needed	42/43

Note:

^aBased on US Preventive Services Task Force grading system.

Abbreviations: LOE, level of evidence; RCT, randomized control trial.